Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | TDP2 | O95551 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 4/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8863229 | 0.86 | LMNA (0.50) | NPC1RAB9ALMNATSHRALDH1A1 | |
| SCHEMBL9738958 | 0.86 | LMNA (0.50) | NPC1RAB9ALMNATSHRALDH1A1 | |
| SCHEMBL1961672 | 0.84 | LMNA (0.49) | NPC1RAB9ALMNATDP1TSHR | |
| SCHEMBL29045186 | 0.83 | NPC1 (0.38) | NPC1RAB9ALMNATBXAS1TDP1 | |
| SCHEMBL2421526 | 0.83 | LMNA (0.54) | NPC1RAB9ALMNATDP1TSHR | |
| SCHEMBL9797904 | 0.81 | TSHR (0.50) | NPC1RAB9ALMNATBXAS1TDP1 | |
| SCHEMBL9005008 | 0.80 | NPC1 (0.37) | NPC1RAB9ATBXAS1KMT2AALDH1A1 | |
| SCHEMBL25475157 | 0.79 | NPC1 (0.40) | NPC1RAB9ALMNATBXAS1KMT2A | |
| SCHEMBL10815933 | 0.79 | KMT2A (0.41) | NPC1RAB9ALMNATBXAS1KMT2A | |
| SCHEMBL29045209 | 0.79 | NPC1 (0.40) | NPC1RAB9ALMNATBXAS1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104818276-B | Single-stranded nucleic acid molecules for controlling gene expression | 株式会社博纳克 | 2020-12-11 | — | — | CN | disclosed |
| US-9206422-B2 | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | BONAC CORPORATION (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9200278-B2 | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | BONAC CORPORATION (JP) | 2015-12-01 | — | — | US | disclosed |
| EP-2639307-B1 | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | BONAC CORP (JP) | 2015-03-04 | — | — | EP | disclosed |
| EP-2628801-B1 | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | BONAC CORP (JP) | 2015-01-07 | — | — | EP | disclosed |
| EP-2674494-B1 | Single-stranded RNA molecule having nitrogen-containing alicyclic skeleton | BONAC CORP (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-20140171633-A1 | Single-Stranded Nucleic Acid Molecule Having Nitrogen-Containing Alicyclic Skeleton | BONAC CORPORATION (JP) | 2014-06-19 | — | — | US | disclosed |
| US-20140171486-A1 | Single-Stranded Nucleic Acid Molecule Having Nitrogen-Containing Alicyclic Skeleton | BONAC CORPORATION (JP) | 2014-06-19 | — | — | US | disclosed |
| EP-2674494-A1 | Single-stranded RNA molecule having nitrogen-containing alicyclic skeleton | Bonac Corporation (JP) | 2013-12-18 | — | — | EP | disclosed |
| EP-2436767-B1 | Single-stranded RNA molecule having nitrogen-containing alicyclic skeleton | BONAC CORP (JP) | 2013-11-20 | — | — | EP | disclosed |
| EP-2639307-A2 | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | Bonac Corporation (JP) | 2013-09-18 | — | — | EP | disclosed |
| EP-2628801-A1 | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton | Bonac Corporation (JP) | 2013-08-21 | — | — | EP | disclosed |
| US-20120035246-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING NITROGEN-CONTAINING ALICYCLIC SKELETON | BONAC CORPORATION (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171633-A1 | Single-Stranded Nucleic Acid Molecule Having Nitrogen-Containing Alicyclic Skeleton | NSUN2, CTDSP1, RNGTT | NPC1 3364/4885RAB9A 4285/4885TDP2 1552/4885 |
| US-20120035246-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING NITROGEN-CONTAINING ALICYCLIC SKELETON | NSUN2, CTDSP1, RNGTT | NPC1 3364/4885RAB9A 4285/4885TDP2 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.